← All trials
NCT02550080
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2015
- Primary completion
- Dec 1, 2018
- Completion date
- May 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 3130
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shandong Provincial Institute of Dermatology and VenereologyLead sponsor
- Shandong Provincial HospitalCollaborator
- Liaocheng People's HospitalCollaborator
- Qingdao Center Medical GroupCollaborator
- Shandong Jining No. 1 People's HospitalCollaborator
- Dezhou People's Hospital,ShandongCollaborator
- Linyi City Dermatology Hospital Prevention and TreatmentCollaborator
- Jining City Dermatology Hospital Prevention and TreatmentCollaborator
- Weifang City Dermatology Hospital Prevention and TreatmentCollaborator
- Laiwu City Dermatology Hospital Prevention and TreatmentCollaborator
- Rizhao City Dermatology Hospital Prevention and TreatmentCollaborator
- Jinan UniversityCollaborator
- Shandong Provincial Institute of Dermatology and VenereologyStudy chair
- Dongying People's Hospital, ShandongCollaborator
- People's Liberation Army of ChinaCollaborator
- Shandong Province Qianfoshan HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.